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Transforming growth factor-b (TGF-b) stimulates the transcription of the a2(I) collagen gene. The dermal ﬁbroblast
activation in systemic sclerosis (SSc) may be a result of stimulation by autocrine TGF-b. In this study, we inves-
tigated whether p38 mitogen-activated protein kinase (MAPK) is involved in TGF-b-induced transcriptional acti-
vation of the human a2(I) collagen gene in normal dermal ﬁbroblasts and in upregulated extracellular matrix (ECM)
expression in SSc ﬁbroblasts. Type I collagen expression induced by TGF-b was suppressed by the specific p38
MAPK inhibitors SB203580 or SB202190 in normal ﬁbroblasts. TGF-b induced phosphorylation and activation of
p38 MAPK in normal dermal ﬁbroblasts. Transient transfection of dominant-negative mutant p38 MAPK into normal
ﬁbroblasts abolished TGF-b-induced promoter activity of the human a2(I) collagen gene in normal ﬁbroblasts.
Moreover, constitutive phosphorylation and activation of p38 MAPK was demonstrated in SSc ﬁbroblasts, and the
inhibition of p38 MAPK using specific p38 MAPK inhibitors or dominant-negative mutant p38 MAPK abolished the
upregulated expression of type I collagen or ﬁbronectin in SSc ﬁbroblasts. These results strongly suggest the
contribution of p38 MAPK signaling to the TGF-b-mediated regulation of the human a2(I) collagen gene in normal
dermal ﬁbroblasts and constitutive upregulated expression of type I collagen and ﬁbronectin in SSc ﬁbroblasts.
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Type I collagen, the most abundant mammalian collagen,
consists of two a1(I) chains and one a2(I) chain, which are
coordinately expressed (Ramirez and DiLiberto, 1990; Vuo-
rio and de Crombrugghe, 1990). Excessive deposition of
type I collagen is characteristic of many fibrotic disorders,
including systemic sclerosis (SSc) (Bornstein and Sage,
1980; Ihn and Tamaki, 2000a), and most likely results from
transcriptional activation of collagen genes in response to
cytokines and other factors present in the prefibrotic/in-
flammatory lesions. The most widely studied cytokine in-
volved in collagen deposition is transforming growth factor-
b (TGF-b).
TGF-b is a highly pleiotropic cytokine that promotes, in-
hibits, and modulates a wide variety of cellular activities and
morphogenetic processes, including extracellular matrix
(ECM) elaboration (Massague¨, 1990). TGF-b influences both
ends of the dynamic balance that is normally maintained
between synthesis and degradation of the ECM (Roberts
et al, 1990). TGF-b has been shown to increase expression
of collagen types I, III, VI, VII, and X, fibronectin, and pro-
teoglycans (Massague¨, 1990). Stimulation of ECM produc-
tion by TGF-b is further enhanced by its inhibitory effect on
matrix degradation, decreasing the synthesis of proteases
and increasing the levels of protease inhibitors (Massague¨,
1990).
Previous studies on cultured fibroblasts have shown that
TGF-b stimulates type I collagen synthesis by acting mostly
at the transcriptional level (Ignotz et al, 1987; Ka¨ha¨ri et al,
1990). Extensive studies have been carried out regarding
transcriptional regulation of the type I collagen gene by
TGF-b. An initial study on the murine a2(I) collagen gene
demonstrated that a member of the CCAAT box binding
factor (CTF)/nuclear factor 1 (NF1) family that binds be-
tween bp 315 and 295 in the murine a2(I) collagen pro-
moter mediates TGF-b stimulation of this promoter (Rossi
et al, 1988). The transcriptional regulation of this promoter in
human fibroblasts differs in some respects, however, from
that of the murine a2(I) collagen promoter. TGF-b stimula-
tion of the human a2(I) collagen promoter was reported to
be mediated by a multiprotein complex that interacts with
two distinct promoter segments (bp 330 to 285 and
271 to 255) termed TbRE (Inagaki et al, 1994, 1995). The
proteins in this complex have been identified as transcrip-
tion factors Sp1 and Sp3 (Ihn et al, 1996; Ihn and Trojan-
owska, 1997). An additional study demonstrated that Sp1 is
required for the response of a2(I) collagen to TGF-b (Green-
wel et al, 1997). Two other studies have suggested that ac-
tivated protein-1 family members are involved in TGF-b
effects in the mouse and human a2(I) collagen promoter
(Chang and Goldberg, 1995; Chung et al, 1996).
Recent studies have identified Smad proteins as major
downstream targets of TGF-b receptor kinases, with im-
Abbreviations: ATF, activating transcription factor; CAT, chloramp-
henicol acetyltransferase; CBP, CREB-binding protein; COL1A2,
a2(I) collagen; dn, dominant negative; ECM, extracellular matrix;
ERK, extracellular signal-regulated kinase; mAB,monoclonal anti-
body; MAPK, mitogen-activated protein kinase; MEK, mitogen-
activated protein kinase kinase; SSc, systemic sclerosis; TbRE,
TGF-b response element; TGF-b, transforming growth factor-b
Copyright r 2005 by The Society for Investigative Dermatology, Inc.
247
portant roles in intracellular TGF-b signaling in vertebra-
tes (Kretzschmar and Massague¨, 1998). Based on their
structure and function, Smads are classified into three
subgroups. The receptor-regulated Smads are directly
phosphorylated and activated by TGF-b receptors. Smad4,
representing a distinct subfamily, oligomerizes with the re-
ceptor-regulated Smads and together these complexes
translocate into the nucleus, where they activate the tran-
scription of TGF-b-inducible genes (Kawabata et al, 1998).
Smad6 and Smad7 inhibit TGF-b signaling by receptor-reg-
ulated Smad. It has also been demonstrated that Smad3
and transcriptional coactivators p300 and CREB-binding
protein (CBP) are involved in TGF-b stimulation of the hu-
man a2(I) collagen gene (Chen et al, 1999; Ghosh et al,
2000).
Recently, other signaling pathways besides the Smad
proteins have also been shown to mediate TGF-b signaling,
and one of these pathways is the p38 mitogen-activated
protein kinase (MAPK) pathway (Kyriakis and Avruch, 1996).
In this study, we investigated whether p38 MAPK is involved
in TGF-b-induced transcriptional activation of the human
a2(I) collagen gene in normal dermal fibroblasts and in up-
regulated type I collagen expression in SSc fibroblasts.
Results
The p38 MAPK inhibitors abolished the increase of type
I collagen in normal dermal ﬁbroblasts stimulated with
TGF-b In order to investigate the possible role of p38 MAPK
in TGF-b-stimulated type I collagen synthesis in normal
dermal fibroblasts, we used the specific p38 MAPK inhib-
itors, SB202190 and SB203580. The condition medium was
collected and clarified by centrifugation, and immunoblot-
ting was performed with a goat monoclonal antibody (mAB)
against human type I collagen. As shown in Fig 1, the p38
MAPK inhibitor SB202190 did not change type I collagen
synthesis significantly (lanes 1–3), but decreased TGF-b (3
ng per mL)-induced type I collagen synthesis in normal fib-
roblasts in a concentration-dependent manner (lanes 7,
9,10). Moreover, SB203580 also abolished TGF-b-induced
type I collagen synthesis in normal fibroblasts in a concen-
tration-dependent manner (lanes 7, 11, 12). But, PD98059,
a specific inhibitor of the mitogen-activated protein kinase
kinase (MEK)1 and MEK2 activation (Alessi et al, 1995;
Dudly et al, 1995), did not abolish TGF-b-induced type I
collagen synthesis in normal fibroblasts (Fig 1, lanes 7,8).
PD98059 upregulated the basal expression of type I colla-
gen protein. Cell viability was determined with trypan blue
stain, which demonstrated that the addition of these con-
centrations of the inhibitors tested did not have cytotoxic
effects.
Northern blot analysis was performed to investigate the
effects of the p38 MAPK inhibitors on the expression of the
human a2(I) collagen gene in normal fibroblasts. As shown
in Fig 2, p38 MAPK inhibitors did not change basal expres-
sion of the a2(I) collagen gene, but inhibited the upregulated
expression of the a2(I) collagen gene by TGF-b (3 ng per
mL) in normal dermal fibroblasts. These results strongly
suggested that p38 MAPK is involved in TGF-b-induced
type I collagen expression in normal dermal fibroblasts.
TGF-b-induced p38 MAPK activation in normal dermal
ﬁbroblasts Since the inhibition of p38 MAPK significantly
decreased TGF-b-induced type I collagen expression in
normal dermal fibroblasts, we determined whether TGF-b
activates p38 MAPK in normal dermal fibroblasts by
immunoblotting using antibodies specific for phosphory-
lated, activated forms of p38 MAPK (Thr180/Tyr182).
Immunoblotting of whole-cell extracts revealed that p38
MAPK Thr180/Tyr182 phosphorylation occurred as early as
15 min after treatment with TGF-b1. The maximal activation
(4.4-fold) was noted at 30 min and a gradual decrease of
p38 MAPK phosphorylation was seen (Fig 3A). The phos-
phorylation of p38 MAPK was shown to be very rapid and
transit, as compared with the previous study (Sato et al,
2002).
The p38 MAPK assay showed that TGF-b1 stimulation
increased the p38 MAPK activity (Fig 3B). The level
of phosphorylated activating transcription factor (ATF)-2
was maximal at 30 min and 1 h (5.8-fold) of incubation with
TGF-b1 (Fig 3B). In addition, SB203580, a specific p38
MAPK inhibitor, considerably inhibited the activation of ATF-
2, whereas PD98059 did not affect the TGF-b1-mediated
induction of phosphorylated ATF-2. These results suggest
that treatment with TGF-b1 results in the activation of p38
MAPK in normal fibroblasts.
Effects of the p38 MAPK inhibitors on the TGF-b-
induced transcriptional activity of the human a2(I)
collagen gene in normal ﬁbroblasts Previous studies on
Figure1
The p38 mitogen-activated protein kinase (MAPK) inhibitors abol-
ished the increase of type I collagen synthesis in normal dermal
fibroblasts stimulated with transforming growth factor-b (TGF-b).
Synthesis of type I collagen in normal fibroblasts was determined by
immunoblotting of tissue culture medium using antibodies to type I
collagen. Comparisons of the reactivities were determined using a
densitometer. Normal dermal fibroblasts (1  105 cells) were seeded in
six-well plates in minimum essential medium (MEM) with 10% fetal calf
serum and grown to confluency. Cells were placed in 0.5 mL of MEM
and 0.1% bovine serum albumin for 24 h prior to the TGF-b1 treatment.
The indicated reagents were added 1 h before the TGF-b1 treatment.
After incubation with or without 3 ng per mL TGF-b1 for 24 h, the
conditioning medium was collected and clarified by centrifugation, and
the cells remaining in the dishes were treated with trypsin and counted
electronically. The samples were normalized for cell number. The ad-
dition of the selective p38 MAPK inhibitor SB202190 or SB203580
abolished the TGF-b-mediated induction of type I collagen synthesis in
a concentration-dependent manner, whereas PD98059, a specific in-
hibitor of mitogen-activated protein kinase kinase (MEK)1 and MEK2
activation, did not change TGF-b-mediated induction of type I collagen
synthesis. Antibodies against b-actin were also used as a loading con-
trol. Cell viability was determined with trypan blue stain, which dem-
onstrated that the addition of these concentrations of the inhibitors
tested did not have cytotoxic effects. Representative result of five
separate experiments is shown.
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cultured fibroblasts have shown that TGF-b stimulates type
I collagen synthesis in normal fibroblasts by acting mostly at
the transcriptional level (Ignotz et al, 1987; Ka¨ha¨ri et al,
1990). Therefore, we examined the effects of p38 MAPK
inhibitors on the promoter activity of the human a2(I) col-
lagen gene in normal fibroblasts. As seen in Fig 4, PD98059
(30 mM) did not change basal promoter activity or TGF-b-
induced promoter activity of the human a2(I) collagen gene.
The addition of either SB202190 or SB203580 did not sig-
nificantly change basal promoter activity of the human a2(I)
collagen gene. On the other hand, the addition of either
SB202190 or SB203580 abolished TGF-b-induced promot-
er activity of the human a2(I) collagen gene in normal
fibroblasts.
The expression of the dominant-negative mutant p38
MAPK repressed the TGF-b-induced transcriptional ac-
tivity of the human a2(I) collagen gene in normal ﬁbro-
blasts To further confirm the role of p38 MAPK in TGF-b-
induced transcriptional activity of the human a2(I) collagen
gene in normal dermal fibroblasts, transient transfection of
the dominant-negative mutant p38 MAPK into normal fib-
roblasts was performed. As shown in Fig 5, transient
transfection of either the dominant-negative mutant p38
MAPKa or the dominant-negative mutant p38 MAPKb did
not significantly change basal promoter activity of the hu-
man a2(I) collagen gene in normal fibroblasts. Transient
transfection of either the dominant-negative mutant p38
MAPKa or the dominant-negative mutant p38 MAPKb,
however, abolished TGF-b-induced promoter activity of the
human a2(I) collagen gene in a concentration-dependent
manner. Cell viability was determined by trypan blue stain,
which demonstrated that transient transfection of these
amounts of dominant-negative mutant p38 MAPK did
not have cytotoxic effects. On the other hand, transient
transfection of the dominant-negative mutant extracellular
signal-regulated kinase (ERK)2 in normal fibroblasts did not
abolish TGF-b-induced promoter activity of the human a2(I)
collagen gene, which indicates that the expression of the
dominant-negative mutant p38 MAPK specifically represses
the TGF-b-induced transcriptional activity of the human
a2(I) collagen gene in normal fibroblasts.
SB203580 -
-
+
-
-
- - -
-
-
-
-
+ +
+
+
+
+SB202190
TGF-β
α1(I)collagen
α2(I)collagen
serum free
3ng/ml TGF–β
GAPDH
300 *
200
α
2(I
) c
oll
ag
en
 m
RN
A
100
N/A 10µM
SB202190
10µM
SB203580
(A)
(B)
Figure 2
Northern blot analysis of the a2(I) collagen gene expression in
normal dermal fibroblasts stimulated with transforming growth
factor-b (TGF-b). (A) Expression of the a1(I) and a2(I) collagen mes-
senger RNA (mRNA) in normal fibroblasts was investigated by northern
blot analysis in the presence or absence of the specific p38 mitogen-
activated protein kinase inhibitors (10 mM). Fibroblasts were treated or
untreated with 3 ng per mL TGF-b1 in the presence or absence of the
indicated inhibitors. (B) The means  SE for the results of four separate
experiments are shown. Values indicate the band density relative to
untreated fibroblasts, which was set at 100. Comparison of each mRNA
expression was made between untreated and TGF-b1-treated normal
fibroblasts under the same conditions (po0.001).
Figure3
Transforming growth factor-b (TGF-b) induced p38 mitogen-acti-
vated protein kinase (MAPK) activation in normal dermal fibro-
blasts. (A) Phosphorylation of p38 MAPK in normal fibroblasts was
determined by immunoblotting using antibodies specific for phos-
phorylated, activated forms of p38 MAPK (Thr180/Tyr182). Immuno-
blotting of whole-cell extracts revealed that p38 MAPK Thr180/Tyr182
phosphorylation occurred after treatment with 3 ng per mL TGF-b1.
TGF-b-induced phosphorylation of p38 MAPK reached the maximum
level after 30 min. Antibodies against p38 MAPK were also used to
confirm that the protein concentrations of p38 MAPK were maintained
with or without TGF-b1 stimulation. Representative result of three sep-
arate experiments is shown. (B) p38 MAPK was collected by immuno-
precipitation, and subjected to an in vitro kinase assay in the presence
of ATF-2 as described in Materials and Methods. In the p38 MAPK
assay, TGF-b1 stimulation (3 ng per mL) increased phosphorylation of
ATF-2. The levels of phosphorylated ATF-2 were maximal 30 min after
stimulation with TGF-b. SB203580 (10 mM) entirely abolished the TGF-
b1-induced (3 ng per mL, for 30 min) activation of ATF-2, whereas
PD98059 (30 mM) did not change TGF-b1-mediated induction of phos-
phorylated ATF-2. Antibodies against b-actin were also used as a
loading control. Cell viability was determined with trypan blue stain,
which demonstrated that the addition of these concentrations of the
inhibitors tested did not have cytotoxic effects. Representative result of
three separate experiments is shown.
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Constitutive phosphorylation and activation of p38
MAPK in SSc ﬁbroblasts Next, to determine whether
p38 MAPK is activated in SSc fibroblasts, the constitutive
phosphorylation of p38 MAPK in SSc and normal fibroblasts
was investigated using serum-deprived SSc and normal
dermal fibroblasts. Detection of the phosphorylated form of
p38 MAPK was performed by immunoblotting using anti-
bodies specific for phosphorylated, activated forms of p38
MAPK (Thr180/Tyr182). Immunoblotting of whole-cell ex-
tracts revealed that constitutive p38 MAPK Thr180/Tyr182
phosphorylation occurred in SSc fibroblasts (Fig 6A, lanes
6–8 and Fig 6B). Antibodies against p38 MAPK were also
used to determine the protein concentrations of p38 MAPK
in SSc and normal fibroblasts, which demonstrated that
SSc and normal fibroblasts had an equivalent amount of
p38 MAPK (Fig 6A). We next examined whether p38 MAPK
phosphorylation detected in SSc fibroblasts was associated
with increased p38 MAPK activity using the p38 MAP kinase
assay. Increased p38 MAPK activity was also detected in
SSc fibroblasts (Fig 6C, lanes 6–8 and Fig 6D).
Constitutive phosphorylation of p38 MAPK was corre-
lated with the increased synthesis of type I collagen and
ﬁbronectin in SSc dermal ﬁbroblasts Next, we investi-
gated the significance of constitutive phosphorylation and
activation of p38 MAPK in SSc fibroblasts. Expression lev-
els of type I collagen and fibronectin were determined in
normal and SSc fibroblasts using immunoblotting. The lev-
els of p38 MAPK phosphorylation in SSc fibroblasts were
correlated with the expression levels of type I collagen and
fibronectin proteins (Fig 6E,F). Note that SSc fibroblasts in
which constitutive p38 MAPK phosphorylation was detect-
ed produced greater amounts of type I collagen and
fibronectin (Fig 6E, lanes 6–8).
Involvement of the p38 MAPK in the upregulated ex-
pression of type I collagen and ﬁbronectin in SSc ﬁb-
roblasts Next, we investigated whether the constitutive
phosphorylation and activation of p38 MAPK in SSc fibro-
blasts is involved in the upregulated ECM expression in SSc
fibroblasts. Expression levels of type I collagen and fibr-
onectin were determined in normal and SSc fibroblasts
in the presence and absence of p38 MAPK inhibitors. The
addition of p38 MAPK inhibitors abolished the upregulated
expression of type I collagen as well as fibronectin in SSc
fibroblasts in a concentration-dependent manner (Fig 7).
SSc fibroblasts were shown to exhibit elevated activity of
the human a2(I) collagen promoter (Ihn et al, 2001b). There-
fore, we examined the effects of p38 MAPK inhibitors on the
promoter activity of the human a2(I) collagen gene. As seen
in Fig 8A, normal fibroblasts treated with p38 MAPK inhib-
itors showed little reduction in the promoter activity of the
human a2(I) collagen gene. The treatment with PD98059
had little effect on the promoter activity of the human a2(I)
collagen gene in SSc fibroblasts. SSc fibroblasts treated
with p38 MAPK inhibitors, however, showed concentration-
dependent reduction in this activity (Fig 8A).
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Figure 4
Effects of the p38 mitogen-activated protein kinase inhibitors on
the transforming growth factor-b (TGF-b)-induced transcriptional
activity of the human a2(I) collagen gene in normal fibroblasts. The
plasmid carrying a 3.5 kb fragment of the human a2(I) collagen pro-
moter was used in transient transfections of normal fibroblasts in the
absence or presence of the indicated inhibitors. These inhibitors were
added 1 h prior to TGF-b1 stimulation (3 ng per mL, for 24 h). Values
indicate the a2(I) collagen promoter activities relative to untreated fib-
roblasts, which were set at 100. The means  SE for four separate
experiments are shown. Comparison of each promoter activity was
made between untreated and TGF-b1-treated normal fibroblasts under
the same conditions (po0.001). Cell viability was determined with
trypan blue stain, which demonstrated that the addition of these con-
centrations of the inhibitors tested did not have cytotoxic effects.
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Figure5
Effects of the dominant-negative mutants of p38 mitogen-activat-
ed protein kinase on the transforming growth factor-b (TGF-b)-in-
duced transcriptional activity of the human a2(I) collagen gene in
normal fibroblasts. The plasmid carrying a 3.5 kb fragment of the
human a2(I) collagen promoter was used in transient transfections of
normal fibroblasts in the absence or presence of the indicated dom-
inant-negative mutants or the vector. Then fibroblasts were treated with
TGF-b1 (3 ng per mL) for 24 h. Values indicate the a2(I) collagen pro-
moter activities relative to the normal fibroblasts untreated and
transfected with the vector, which was set at 100. The means  SE
for four separate experiments are shown. Comparison of each pro-
moter activity was made between untreated and TGF-b1-treated nor-
mal fibroblasts under the same conditions (po0.01). Cell viability was
determined with trypan blue stain, which demonstrated that transient
transfection of the plasmids did not have cytotoxic effects.
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To further confirm the role of p38 MAPK in the upregu-
lated transcriptional activity of the human a2(I) collagen
gene in SSc fibroblasts, transient transfection of the dom-
inant-negative mutant p38 MAPK into SSc fibroblasts was
performed. As shown in Fig 8B, transient transfection of
either the dominant-negative mutant p38 MAPKa or the
dominant-negative mutant p38 MAPKb did not significantly
change the basal promoter activity of the human a2(I) col-
lagen gene in normal fibroblasts. But transient transfection
of either the dominant-negative mutant p38 MAPKa or the
dominant-negative mutant p38 MAPKb abolished the up-
regulated promoter activity of the human a2(I) collagen gene
in SSc fibroblasts in a concentration-dependent manner.
Cell viability was determined by trypan blue stain, which
demonstrated that transient transfection of these amounts
of dominant-negative mutant p38 MAPK did not have
cytotoxic effects. On the other hand, transient transfection
of the dominant-negative mutant ERK2 in SSc fibroblasts
did not abolish the upregulated promoter activity of
the human a2(I) collagen gene in SSc fibroblasts, which
indicates that the expression of the dominant-negative
mutant p38 MAPK specifically represses the upregulated
transcriptional activity of the human a2(I) collagen gene in
SSc fibroblasts.
Discussion
Excessive ECM deposition in the skin, lungs, or other or-
gans is a hallmark of SSc. The pathogenesis of SSc is still
poorly understood, but increasing evidence suggests that
activation of lesional fibroblasts contributes to the fibrotic
process (Jelaska et al, 1996; Ihn et al, 2001b). The mech-
anism of dermal fibroblast activation in SSc is presently
unknown; however, many of the characteristics of SSc fib-
roblasts resemble those of normal fibroblasts stimulated by
TGF-b (LeRoy et al, 1989; Ihn et al, 2001b), suggesting that
the dermal fibroblast activation in SSc may be a result of
stimulation by autocrine TGF-b. This notion is supported by
our recent findings that SSc fibroblasts express elevated
expression levels of TGF-b receptor types I and II and that
this correlates with elevated expression levels of type I col-
lagen (Ihn et al, 2001b; Yamane et al, 2002).
This study demonstrated constitutive phosphorylation
and activation of p38 MAPK in SSc fibroblasts (Fig 6A–D),
which was correlated with increased expression of type I
collagen and fibronectin (Fig 6E and F). During the prep-
aration of this paper, Sato et al reported that some SSc
fibroblasts showed increased phosphorylation of p38 MAPK
(Sato et al, 2002), which is consistent with our results. They
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Figure 6
Constitutive phosphorylation and activation of p38 mitogen-activated protein kinase (MAPK) in systemic sclerosis (SSc) fibroblasts. (A)
Phosphorylation of p38 MAPK in normal and SSc fibroblasts was determined by immunoblotting using antibodies specific for phosphorylated,
activated forms of p38 MAPK (Thr180/Tyr182). Immunoblotting of whole-cell extracts revealed that constitutive p38 MAPK Thr180/Tyr182 phos-
phorylation occurred in SSc fibroblasts. Antibodies against p38 MAPK were also used to confirm that the protein concentrations of p38 MAPK were
maintained between normal and SSc fibroblasts. Representative result of four separate experiments is shown. (B) Quantitative analysis of levels of
p38 MAPK phosphorylation. The means  SE for the results of four separate experiments are shown. Values indicate the band density relative to
normal fibroblasts, which was set at 100. Comparison of constitutive levels of p38 MAPK phosphorylation was made between normal and SSc
fibroblasts under the same conditions (po0.001). (C) p38 MAPK was collected by immunoprecipitation, and subjected to an in vitro kinase assay in
the presence of ATF-2 as described in Materials and Methods. In the p38 MAPK assay, constitutive activated p38 MAPK increased phosphorylation
of ATF-2 in SSc fibroblasts. Antibodies against ATF-2 were also used as a loading control. Representative result of four separate experiments is
shown. (D) Quantitative analysis of the p38 MAPK activities. The means  SE for the results of four separate experiments are shown. Values indicate
the band density relative to normal fibroblasts, which was set at 100. Comparison of each p38 MAPK activity was made between normal and SSc
fibroblasts under the same conditions (po0.001). (E) Expression levels of type I collagen and fibronectin were determined in normal and SSc
fibroblasts using immunoblotting. The levels of p38 MAPK phosphorylation in SSc fibroblasts were correlated with the expression levels of type I
collagen and fibronectin proteins. Antibodies against b-actin were also used as a loading control. Representative results of four separate ex-
periments is shown. (F) Quantitative analysis of type I collagen and fibronectin protein levels. The means  SE for the results of four separate
experiments are shown. Values indicate the band density relative to normal fibroblasts, which was set at 100. Comparison of each protein
expression was made between normal and SSc fibroblasts under the same conditions (po0.001).
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concluded, however, that the phosphorylation of p38 MAPK
was not correlated with collagen production, which is not
consistent with our results. At this point, the reason for this
discrepancy is not clear, but it may be partially because of
the different patient populations, and further studies are re-
quired to address this point. But the inhibition of p38 MAPK
by p38 MAPK inhibitors or dominant-negative mutant p38
MAPK abolished the upregulated expression of type I col-
lagen or fibronectin in SSc fibroblasts (Figs 7 and 8), which
suggests the crucial role of p38 MAPK in upregulated ex-
pression of ECM in SSc fibroblasts. Basal activation of p38
MAPK was not detected in all SSc fibroblasts lines. This
may suggest that SSc fibroblasts have heterogeneity and
that p38 MAPK plays a role in some parts of SSc patients.
TGF-b is a multifunctional peptide that regulates cell
growth and differentiation (Roberts and Sporn, 1993). It is
important in the developmental process, regulating the im-
mune response, and plays a fundamental role in ECM for-
mation (Roberts and Sporn, 1993). TGF-b has been shown
to induce many tissue repair factors, and its pathogenic role
in the development of fibrosis is becoming increasingly
clear (Border and Noble, 1994). Recent studies have iden-
tified Smad proteins as major downstream targets of TGF-b
receptor kinases (Kretzschmar and Massague¨, 1998). As for
the collagen gene, the synergistic cooperation between Sp1
and Smad3/Smad4 was shown to be required for TGF-b
response of the type I collagen gene (Zhang et al, 2000;
Poncelet and Schnaper, 2001), and the cooperation of
p300/CBP with Smad was demonstrated in TGF-b re-
sponse of the type I collagen gene (Chen et al, 1999; Ghosh
et al, 2000). Other signaling pathways besides the Smad
proteins have also been shown to mediate TGF-b signaling,
and these pathways include the p38 MAP pathway (Kyriakis
and Avruch, 1996). In human dermal fibroblasts, collagen-
dependent induction of matrix metalloproteinase (MMP)-13
requires p38 MAPK activity (Ravanti et al, 1999a). In human
gingival fibroblasts, TGF-b1 induces MMP-13 via p38
MAPK (Ravanti et al, 1999b). In this study, we showed that
the stimulation of human normal dermal fibroblasts by TGF-
b1 resulted in the phosphorylation and activation of p38
MAPK. The TGF-b1-mediated induction of a2(I) collagen
gene expression was significantly inhibited by selective p38
MAPK inhibitors, but not by a selective MEK1/2 inhibitor
PD98059 in normal fibroblasts. TGF-b1-mediated transcrip-
tional activation of the a2(I) collagen gene was significantly
inhibited by selective p38 MAPK inhibitors or transfection of
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Figure 7
Effects of the p38 mitogen-activated protein kinase (MAPK) inhibitors on the upregulated expression of type I collagen and fibronectin in
systemic sclerosis (SSc) fibroblasts. Expression levels of type I collagen (A, B) and fibronectin (C, D) in normal and SSc fibroblasts were
determined by immunoblotting of tissue culture medium using antibodies to type I collagen or fibronectin. The addition of the selective p38 MAPK
inhibitor SB202190 or SB203580 abolished the upregulated expression of type I collagen and fibronectin in SSc fibroblasts in a concentration-
dependent manner, whereas PD98059, a specific inhibitor of mitogen-activated kinase kinase (MEK)1 and MEK2 activation, did not change the
expression levels of type I collagen. Cell viability was determined with trypan blue stain, which demonstrated that the addition of these con-
centrations of the inhibitors tested did not have cytotoxic effects. Antibodies against b-actin were also used as a loading control. Representative
result of four separate experiments is shown (A, C). Quantitative analysis of type I collagen (B) and fibronectin (D) proteins. The means  SE for the
results of four separate experiments are shown. Values indicate the band density relative to normal fibroblasts, which was set at 100. Comparison of
each p38 MAPK activity was made between normal and SSc fibroblasts under the same conditions (po0.001).
252 IHN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
the dominant-negative mutant p38 MAPK in normal fibro-
blasts. These results suggest that the p38 MAPK pathway is
involved in the regulation of the collagen gene by TGF-b1 in
normal fibroblasts. As described above, the dermal fibro-
blast activation in SSc may be a result of stimulation by
autocrine TGF-b. Therefore, there was a possibility that
constitutive phosphorylation and activation of p38 MAPK in
SSc fibroblasts may be a result of stimulation by autocrine
TGF-b, which is consistent with these results.
In conclusion, this study demonstrated constitutive
phosphorylation and activation of p38 MAPK in SSc fibro-
blasts and the contribution of p38 MAPK signaling both to
the TGF-b-mediated regulation of the human a2(I) collagen
gene in normal fibroblasts and to the constitutive upregu-
lated ECM expression in SSc fibroblasts. Our results raise
the possibility of the development of a therapy for fibrosis,
especially for SSc, using an approach that inhibits the p38
MAPK pathway.
Materials and Methods
Cytokines and other materials Recombinant human TGF-b1 was
purchased from R&D Systems Inc. (Minneapolis, Minnesota).
SB203580, SB202190, and PD98059, which were obtained from
Calbiochem Corp. (La Jolla, California), were dissolved in dimethyl
sulfoxide (DMSO). Controls were incubated with an equal concen-
tration of DMSO. The p38 MAPK rabbit polyclonal antibody was
purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, Cal-
ifornia). The phospho-p38 MAPK (Thr180/Tyr182) rabbit polyclonal
antibody and ATF-2 fusion protein were obtained from New Eng-
land Biolabs (Beverly, Massachusetts). Protein G sepharose was
obtained from Zymed Laboratories Inc. (San Francisco, California).
Cell cultures Human adult skin fibroblasts were obtained by
skin biopsy from the affected areas (dorsal forearm) of seven rand-
omly selected patients with diffuse cutaneous SSc of less than 2 y’
duration. Control fibroblasts were obtained from skin biopsy
specimens from seven healthy donors. Institutional Review Board
approval and written informed consent were obtained according to
the Declaration of Helsinki. The controls were matched with each
SSc patient for age, sex, and biopsy site, and their specimens were
processed in parallel. Primary explant cultures were established in
25 cm2 culture flasks in minimum essential medium (MEM) sup-
plemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, and
50 mg per mL amphotericin (Ihn et al, 1997; Ihn and Tamaki, 2000b).
Fibroblast cultures independently isolated from different individuals
were maintained as monolayers at 371C in 95% air, 5% CO2, and
studied between the third and sixth subpassages. Cell viability was
determined by trypan blue stain (Ihn and Tamaki, 2000c).
Western blot analysis Dermal fibroblasts (1  105 cells) were
seeded in six-well plates in MEM with 10% FCS and grown to
confluency. For the preparation of media collection from dermal
fibroblasts, cells were placed in 0.5 mL of MEM and 0.1% bovine
serum albumin (BSA) for 24 h prior to the cytokine treatment. After
incubation with the indicated reagent for 24 h, the condition me-
dium was collected and clarified by centrifugation, and the cells
remaining in the dishes were treated with trypsin and counted
electronically. Immunoblotting was performed as described previ-
ously (Ihn and Trojanowska, 1997; Ihn and Tamaki, 2000a, c). The
samples (10 mL) were normalized for cell number, subjected to
electrophoresis on 7.5% gradient sodium dodecyl sulfate (SDS)-
polyacrylamide gels, and transferred onto nitrocellulose filters. The
nitrocellulose filters were then incubated with a goat mAB against
human type I collagen (Southern Biotechnology Associates Inc.,
Birmingham, Alabama) or a mouse mAB against human fibronectin
(Santa Cruz Biotechnology). Then, the filters were incubated over-
night with horseradish peroxidase-conjugated secondary antibod-
ies and immunoreactive bands were visualized using an enhanced
chemilunescent system (ECL, Amersham Corporation Piscataway,
New Jersey) according to the manufacturer’s recommendations.
The densities of bands were measured using a densitometer.
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Figure 8
Involvement of p38 mitogen-acitvated protein kinase in the up-
regulated transcriptional activity of the human a2(I) collagen gene
in systemic sclerosis (SSc) fibroblasts. (A) The plasmid carrying a
3.5 kb fragment of the human a2(I) collagen promoter was used in
transient transfections of normal and SSc fibroblasts in the absence or
presence of the indicated inhibitors. Values indicate the a2(I) collagen
promoter activities relative to untreated normal fibroblasts, which was
set at 100. The means  SE for four separate experiments are shown.
Comparison of each promoter activity was made with untreated normal
fibroblasts (po0.001). Cell viability was determined with trypan blue
stain, which demonstrated that the addition of these concentrations of
the inhibitors tested did not have cytotoxic effects. (B) The plasmid
carrying a 3.5 kb fragment of the human a2(I) collagen promoter was
used in transient transfections of normal and SSc fibroblasts in the
absence or presence of the indicated dominant-negative mutants or
the vector. Values indicate the a2(I) collagen promoter activities relative
to the normal fibroblasts transfected with the vector, which was set at
100. The means  SE for four separate experiments are shown. Com-
parison of each promoter activity was made with normal fibroblasts
transfected with the vector (po0.01). Cell viability was determined
with trypan blue stain, which demonstrated that transient transfection
of the plasmids did not have cytotoxic effects.
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RNA preparation and northern blot analysis Fibroblasts were
grown to confluence in MEM supplemented with 10% FCS and
incubated for 24 h in serum-free medium (MEM plus 0.1% BSA)
before addition of the indicated reagent. Total RNA was extracted
and analyzed by northern blotting as described previously (Ihn
et al, 1997; Ihn and Tamaki, 2000a). Filters were sequentially hy-
bridized with probes for a2(I) procollagen, and glyceraldehyde-
3-phosphate dehydrogenase. The filters were scanned with a
densitometer.
Plasmid construction Generation of a 3500 COL1A2/CAT con-
struct consisting of the human collagen a2(I) gene fragment (þ 58
to 3500 bp relative to the transcription start site) linked to the
chloramphenicol acetyltransferase reporter gene was previously
described (Ihn et al, 1996, 1997; Ihn and Trojanowska, 1997; Ihn
and Tamaki, 2000b). Dominant-negative mutants (TGY–AGF) of
p38 a (dn p38 a) and p38b (dn p38b) MAPK were generously pro-
vided by Dr Jiahuai Hans (The Scripps Research Institute, La Jolla,
California) (Wang et al, 1998). The plasmids used encode the ERK2
(p42 MAPK) cDNA in which Thr183 and Tyr185, which must be
phosphorylated for activity were replaced with either glutamic acid
or alanine and phenylalanine, thus rendering the protein inactive
(Ihn and Tamaki, 2000c). Plasmids used in transient transfection
assays were twice purified on CsCl gradients. At least two different
plasmid preparations were used for each experiment.
Transient transfection and chloramphenicol acetyltransferase
assay Human fibroblasts were grown to 80% confluence in 100-
mm dishes in Dulbecco’s MEM containing 10% FCS. Monolayers
were washed, and cells were transfected by the Lipofectin tech-
nique (FuGene 6 Transfectin Reagent, Roche Diagnostic, Indiana-
polis, Indiana) (Ihn et al, 2001a, b, 2002) with 5 mg of 3500
COL1A2/ chloramphenicol acetyltransferase constructs. pSV-b-
galactosidase control vector (Promega, Madison, Wisconsin) was
co-transfected to normalize for transfection efficiency (Ihn et al,
2001a, b, 2002). After incubation overnight, the medium was re-
placed with MEM containing 0.1% BSA or with MEM containing
various amounts of TGF-b, and incubation was continued for 48 h.
Cells were harvested in 0.25 M Tris-HCl (pH 8) and fractured by
freeze-thawing. Extracts, normalized for protein content as meas-
ured by the Bio-Rad reagent, were incubated with butyryl-CoA and
[14C]chloramphenicol for 90 min at 371C. Butyrated chlorampheni-
col was extracted using an organic solvent (2:1 mixture of tetra-
methylpentadecane and xylene) and quantitated with scintillation
counting. Each experiment was performed in duplicate. The Mann–
Whitney U test was used to determine statistical significance.
Assays of p38 MAPK activation The activation of p38 MAPK was
determined by immunoblotting using antibodies specific for phos-
phorylated, activated forms of p38 MAPK (Thr180/Tyr182) (New
England Biolabs) (Matsumoto et al, 1999).
In both experiments, fibroblasts were serum-starved for 24 h
and treated with cytokines for the indicated time. Then, the con-
ditioned medium was removed and the cells were washed with ice-
cold phosphate-buffered saline. The cells were lysed by scraping
into solubilization buffer (50 mM Tris/Cl, pH 8, 150 mM NaCl, 2 mM
EDTA, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2 mM
phenylmethylsulfonyl fluoride, 10 mg per mL aprotinin, 10 mg per
mL leupeptin, and 10 mg per mL pepstatin). The lysate was incu-
bated at 41C for 30 min and then centrifuged for 5 min at 41C.
Protein concentrations of lysates were determined using a Bio-Rad
(Hercules, California) Protein Assay, as recommended by the
manufacturer.
Immunoblotting was performed as described above. Cell
lysates (30 mg) obtained from fibroblasts were subjected to elect-
rophoresis on 10%/20% gradient SDS-polyacrylamide gels, and
transferred onto nitrocellulose filters. The nitrocellulose filters were
then incubated overnight with mAB specific for phosphorylated,
activated forms of p38 MAPK (Thr180/Tyr182) (1:1000 dilution).
Bound antibodies were detected with horseradish peroxidase-
conjugated anti-rabbit immunoglobulin G (IgG) and immunoreac-
tive bands were visualized using an ECL system as described
above. Antibodies against p38 MAPK (Santa Cruz Biotechnology
Inc.) were also used to confirm that the protein concentrations of
p38 MAPK were maintained.
In p38 MAP kinase assay (Matsumoto et al, 1999), 200 mg of the
lysates were incubated with an immobilized phospho-p38 MAPK
(Thr180/Tyr182) mAB overnight at 41C for immunoprecipitation. For
kinase assays, the beads were incubated with 200 mM adenosine
triphosphate and 2 mg ATF-2 fusion protein as a substrate for p38
MAPK at 301C for 30 min. The reaction was terminated with 25 mL
of an SDS sample buffer. The samples were then boiled and sub-
jected to SDS-polyacrylamide gel electrophoresis and transferred
to nitrocellulose membranes. Membranes were incubated over-
night with a phospho-ATF-2 (Thr71) antibody (New England Bio-
labs) overnight at 41C. The membranes were washed, and then
incubated with horseradish peroxidase-conjugated anti-rabbit IgG,
and immunoreactive bands were visualized with ECL.
Statistical analysis Statistical analysis was carried out using the
Mann–Whitney test for the comparisons of means. p values less
than 0.05 were considered significant.
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